VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) VectorY Therapeutics, a leader in vectorized antibody therapies for…
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces…
ZCG-Backed Unimed Acquires Regenboog Shipping Pharmacy Universal Maritime Solutions a leading global provider of medical and compliance solutions to the maritime industry, today announced the acquisition of Regenboog Shipping Pharmacy, a…
Ethris and German Center for Infection Research (DZIF) Announce Strategic Collaboration to Develop mRNA-Based Vaccines Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center…
Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening Median Technologies developer of eyonis®, a suite of artificial intelligence…
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence Evinova today announced that Bristol Myers Squibb has signed an agreement to optimize clinical trials…
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) Genentech, a member of the Roche Group announced today…
Roche’s fenebrutinib becomes the first investigational therapy in over a decade to slow disability progression in primary progressive multiple sclerosis (PPMS) Roche announced today new late-breaking data from the Phase…
Dr. Joseph Chang Launches Update to Bestselling Book “The Aging Myth” With 15 More Years of Breakthrough Research on Cellular Wellness Nu Skin Enterprises Inc. today announced the relaunch of…
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational…
Rapid Medical’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from…
A Legacy of Brighter Smiles: Celebrating 24 Years of the Give Kids A Smile Program The American Dental Association Foundation (ADAF) is officially kicking off Give Kids A Smile® (GKAS) 2026…